ZVRA
Income statement / Annual
Last year (2023), Zevra Therapeutics, Inc.'s total revenue was $27.46 M,
an increase of 162.58% from the previous year.
In 2023, Zevra Therapeutics, Inc.'s net income was -$46.05 M.
See Zevra Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$27.46 M
|
$10.46 M
|
$28.65 M
|
$13.29 M
|
$12.84 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$3.95 M |
$343,000.00 |
$2.06 M |
$1.31 M |
$2.95 M |
$324,000.00 |
$336,000.00 |
$175,000.00 |
$84,000.00 |
$0.00 |
Gross Profit |
$23.51 M |
$10.12 M |
$26.59 M |
$11.98 M |
$9.89 M |
-$324,000.00 |
-$336,000.00 |
-$175,000.00 |
-$84,000.00 |
$0.00 |
Gross Profit Ratio |
0.86 |
0.97 |
0.93 |
0.9 |
0.77 |
0 |
0 |
0 |
0 |
0 |
Research and Development
Expenses |
$38.80 M
|
$19.61 M
|
$10.16 M
|
$8.84 M
|
$19.42 M
|
$41.76 M
|
$20.59 M
|
$20.47 M
|
$13.93 M
|
$11.92 M
|
General & Administrative
Expenses |
$0.00
|
$15.34 M
|
$8.70 M
|
$7.92 M
|
$10.82 M
|
$12.51 M
|
$12.77 M
|
$14.00 M
|
$8.88 M
|
$4.53 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$93.00
|
Selling, General &
Administrative Expenses |
$34.31 M
|
$15.34 M
|
$8.70 M
|
$7.92 M
|
$10.82 M
|
$12.51 M
|
$12.77 M
|
$14.00 M
|
$8.88 M
|
$4.53 M
|
Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$31.82 M |
$0.00 |
Operating Expenses |
$73.11 M |
$34.96 M |
$18.86 M |
$16.76 M |
$30.23 M |
$54.27 M |
$33.37 M |
$34.47 M |
$22.81 M |
$16.44 M |
Cost And Expenses |
$77.07 M |
$35.30 M |
$20.92 M |
$18.07 M |
$33.18 M |
$54.27 M |
$33.37 M |
$34.47 M |
$22.81 M |
$16.44 M |
Interest Income |
$4.54 M |
$760,000.00 |
$248,000.00 |
$89,000.00 |
$309,000.00 |
$420,000.00 |
$365,000.00 |
$353,000.00 |
$32,000.00 |
$4,283.00 |
Interest Expense |
$1.50 M |
$335,000.00 |
$376,000.00 |
$7.09 M |
$6.51 M |
$7.09 M |
$7.34 M |
$7.13 M |
$2.67 M |
$2.72 M |
Depreciation &
Amortization |
$1.01 M
|
$944,000.00
|
$257,000.00
|
$273,000.00
|
$304,000.00
|
$324,000.00
|
$336,000.00
|
$175,000.00
|
$84,000.00
|
$74,763.00
|
EBITDA |
-$48.60 M
|
-$24.08 M
|
$7.98 M
|
-$4.69 M
|
-$20.03 M
|
-$53.52 M
|
-$32.67 M
|
-$34.12 M
|
-$22.81 M
|
-$16.36 M
|
EBITDA Ratio |
-1.77 |
-2.3 |
0.28 |
-0.35 |
-1.56 |
0 |
0 |
0 |
0 |
0 |
Operating Income Ratio
|
-1.81
|
-2.38
|
0.27
|
-0.36
|
-1.58
|
0
|
0
|
0
|
0
|
0
|
Total Other
Income/Expenses Net |
$3.56 M
|
-$17.49 M
|
-$16.25 M
|
-$8.01 M
|
-$4.21 M
|
$4.34 M
|
-$3.09 M
|
$24.72 M
|
-$31.82 M
|
-$5.32 M
|
Income Before Tax |
-$46.05 M |
-$42.33 M |
-$8.52 M |
-$12.79 M |
-$24.54 M |
-$56.59 M |
-$43.43 M |
-$16.53 M |
-$54.64 M |
-$24.48 M |
Income Before Tax Ratio
|
-1.68
|
-4.05
|
-0.3
|
-0.96
|
-1.91
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$0.00 |
-$786,000.00 |
$34,000.00 |
-$34,000.00 |
-$22,000.00 |
-$126,000.00 |
-$43,000.00 |
-$15,000.00 |
$26,000.00 |
-$22,247.00 |
Net Income |
-$46.05 M |
-$41.54 M |
-$8.56 M |
-$12.76 M |
-$24.52 M |
-$56.47 M |
-$43.39 M |
-$16.52 M |
-$54.66 M |
-$24.45 M |
Net Income Ratio |
-1.68 |
-3.97 |
-0.3 |
-0.96 |
-1.91 |
0 |
0 |
0 |
0 |
0 |
EPS |
-1.3 |
-1.2 |
-0.29 |
-3.21 |
-13.23 |
-50.39 |
-47.37 |
-18.1 |
-118.69 |
-31.79 |
EPS Diluted |
-1.3 |
-1.2 |
-0.29 |
-3.21 |
-13.23 |
-50.39 |
-47.37 |
-18.1 |
-118.69 |
-31.79 |
Weighted Average Shares
Out |
$35.45 M
|
$34.49 M
|
$29.77 M
|
$3.98 M
|
$1.85 M
|
$1.12 M
|
$915,806.00
|
$912,315.00
|
$460,542.00
|
$769,239.00
|
Weighted Average Shares
Out Diluted |
$35.45 M
|
$34.49 M
|
$29.77 M
|
$3.98 M
|
$1.85 M
|
$1.12 M
|
$915,806.00
|
$912,315.00
|
$460,542.00
|
$769,239.00
|
Link |
|
|
|
|
|
|
|
|
|
|